UCB buys its way to epilep­sy show­down with Jazz with $1.9B Zo­genix ac­qui­si­tion

Zo­genix’s epilep­sy drug Fin­tepla may on­ly have brought in around $100 mil­lion of sales in its first year, but UCB clear­ly be­lieves it can go much, much high­er.

The Bel­gian phar­ma has inked a $1.9 bil­lion deal to buy out Zo­genix, pay­ing $26 per share in cash and of­fer­ing a con­tin­gent val­ue right worth $2 more per share if Fin­tepla lands an ex­tra EU ap­proval by the end of 2023.

But even the up­front marks a 72% pre­mi­um to Cal­i­for­nia-based Zo­genix’s shares, which were trad­ing just north of $15 on Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.